ChemAbout

ChemAbout is a B2B platform where chemical buyers and suppliers discover each other.

Post a purchase requestList your products (for suppliers)
© 2026 ChemAbout
Compound Index|Demand Board|Insights|Exhibitions|Compliance|Help Center|Privacy Policy|Terms of Service|[email protected]
Home/Compounds/API/N-[(1R)-1-Borono-3-methylbutyl]-Nalpha-(pyrazine-2-carbonyl)-D-phenylalaninamide
C19H25BN4O4
384.2 g/mol
API

B-[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid

CAS1132709-15-9
Category
API
Compound Class
Peptide
Primary Use
Pharmaceutical Raw Material

This compound is a boronic acid derivative featuring a pyrazine-2-carbonylamino group and a phenylalanine-like backbone. It is used as an active pharmaceutical ingredient in pharmaceutical manufacturing and research.

Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→

Related Compounds

ReferenceSame Category

Hirudin

CAS113274-56-9

pharmaceutical raw material

ReferenceSame Category

Quizartinib dihydrochloride

CAS1132827-21-4

pharmaceutical raw material

ReferenceSame Category

Dasabuvir

CAS1132935-63-7

pharmaceutical raw material

ReferenceSame Category

(RS)-baclofen

CAS1134-47-0

pharmaceutical raw material

Referencestereoisomer of

Bortezomib

CAS179324-69-7

pharmaceutical raw material

Referencesame scaffold

N-(2-Pyrazinylcarbonyl)-L-phenylalanine

CAS114457-94-2

pharmaceutical intermediate

Referencesame scaffold

N-(2-Pyrazinylcarbonyl)-L-phenylalanine sodium salt

CAS1093959-75-1

pharmaceutical intermediate

Referencesame scaffold

5-methyl-N-(2-(4-sulfamoylphenyl)ethyl)pyrazine-2-carboxamide

CAS33288-71-0

pharmaceutical intermediate

Related Reading

Therapeutic Peptides in 2026: This Year's Breakthroughs

2026 has been a concentrated year for peptide therapeutics. Efficacy reached a new high in late-stage trials, the obesity field moved beyond the incretins to amylin, the oral route reached weight management, and peptide-guided radioligand therapy kept advancing — each point tied to a specific 2025–2026 result.

Read more
Identifiers
IUPAC Name

[(1R)-3-methyl-1-[[(2R)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid

InChIKey

GXJABQQUPOEUTA-WBVHZDCISA-N

SMILES

B([C@H](CC(C)C)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

Synonyms (12)
  • Boronic acid, B-[(1R)-3-methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]-; B-[(1R)-3-Methyl-1-[[(2R)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic acid; bortezomib diastereomer (R,R) (USP); bortezomib related compound A (USP)
  • (1R,2R)-Bortezomib
  • (1R,2R)-Bortezomib (>85%)
  • Bortezomib (1R, 2R)-Isomer
  • Bortezomib Impurity 7
  • Bortezomib, (1R,2R)-

Sourcing this compound?

Post a free purchase request — no account needed. It reaches suppliers of this product, and replies go straight to your inbox.

Post a Purchase Request→Supplier? List your product for this CAS→